Showing 4201-4210 of 10733 results for "".
- Paroxetine Linked to Neurovascular and Immune Proteomic Changes in Refractory Rosacea: Analysishttps://practicaldermatology.com/news/paroxetine-linked-to-neurovascular-and-immune-proteomic-changes-in-refractory-rosacea/2487517/A secondary analysis of a randomized clinical trial in JAMA Dermatology identified systemic proteomic changes associated with paroxetine treatment in patients with refractory erythematous rosacea, offering new insight into
- FDA Expands Dupilumab CSU Indication to Children as Young as 2 Yearshttps://practicaldermatology.com/news/dupilumab-approval-expanded-to-include-children-as-young-as-2-years-with-csu/2487479/The US Food and Drug Administration (FDA) has expanded the indication for dupilumab (Dupixent; Sanofi and Regeneron) to include pediatric patients aged 2 to 11 years with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. The label expansion, according
- Review: Emerging Therapies Expand Options for Patients With Genodermatoseshttps://practicaldermatology.com/news/review-emerging-therapies-expand-options-for-patients-with-genodermatoses/2487464/A new review published in the Journal of Drugs in Dermatology spotlighted recent advances in the diagnosis, classification, and treatment of several common genodermatoses, incl
- FDA Approves EBGLYSS 8-Week Dosings in Atopic Dermatitishttps://practicaldermatology.com/news/fda-approves-ebglyss-8-week-dosings-in-atopic-dermatitis/2487424/The US Food and Drug Administration (FDA) has approved an every-8-week maintenance dosing regimen for EBGLYSS® (lebrikizumab-lbkz) in adults and adolescents aged 12 years and older weighing at least 40 kg with moderate-to-severe atopic dermatitis, according to an
- BE BOLD at 16 Weeks: Bimekizumab Outperforms Risankizumab for PsAhttps://practicaldermatology.com/news/bimekizumab-outperforms-risankizumab-for-psa/2487356/New data from the Phase 3 BE BOLD study show that bimekizumab (Bimzelx; UCB) achieved superior joint responses compared with risankizumab (Skyriz
- Analysis: Pediatric Allergic Rhinitis Doubled in Japan Over 40 Yearshttps://practicaldermatology.com/news/analysis-pediatric-allergic-rhinitis-doubled-in-japan-over-40-years/2487238/A 40-year epidemiologic analysis published in the World Allergy Organization Journal showed an increases in allergic rhinitis (AR), allergic conjunctivitis (AC), and Japanese cedar pollinosis (JCP) among school-aged children in western Japan, while rates of atopic dermatitis (AD) and bro
- PanOxyl Portfolio Highlights Accessibility and Long-Term Acne Management During Virtual Desksidehttps://practicaldermatology.com/news/panoxyl-portfolio-highlights-accessibility-and-long-term-acne-management-during-virtual-deskside/2487257/Acne management requires a broader approach than simply targeting active breakouts, according to speakers during a virtual media deskside hosted by Revance. The discussion focused on over-the-counter acne management strategies with the PanOxyl brand as well as procedural options for acne scar tre
- Randomized Trial Evaluates Educational Delivery Methods for Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/randomized-trial-evaluates-educational-delivery-methods-for-pediatric-atopic-dermatitis/2487170/A randomized controlled trial published online in Pediatric Dermatology found that video-based therapeutic patient education (TPE) did not significantly outperform standard educational handouts for pediatric atopic dermatiti
- Isotretinoin Use in Adolescence Not Linked to Reduced Adult Height: Analysishttps://practicaldermatology.com/news/isotretinoin-use-in-adolescence-not-linked-to-reduced-adult-height-analysis/2487168/Concerns that isotretinoin therapy during adolescence could impair skeletal growth were not supported by findings from a large nationwide Danish study published in
- BE BOLD: Bimekizumab Tops Risankizumab for ACR50 Outcomeshttps://practicaldermatology.com/news/be-bold-bimekizumab-tops-risankizumab-for-acr50-outcomes/2487139/New phase 3 data from the BE BOLD trial indicated that bimekizumab (BIMZELX) achieved superior joint efficacy compared with risankizumab (SKYRIZI) in adults with active psoriatic arthritis (PsA), according to a press release from the manufacturer.